GlassScriptPhysician profile
Amaryllis Gil
NPI 1235116591
$3,025.43
in general payments reported to CMS, 2019-2025
19 companies · $354 in 2025
The $354 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $19.32 · 2021: $140 · 2022: $53.42 · 2023: $34.98 · 2024: $2,241 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,462 · Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,462.37 |
| Food and Beverage | $1,167.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $2,018.61 | 2024 | |
| Genentech USA, INC. | $143.61 | 2019-2025 | Columvi |
| Novartis Pharmaceuticals Corporation | $138.80 | 2024-2025 | |
| Advanced Accelerator Applications | $115.63 | 2019 | |
| Merck Sharp & Dohme LLC | $95.54 | 2019-2025 | Keytruda |
| Gilead Sciences, INC. | $76.94 | 2021-2025 | Trodelvy |
| Pfizer INC. | $73.09 | 2019-2025 | |
| Tempus Ai, INC | $48.78 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $40.02 | 2022-2025 | Eliquis |
| Janssen Biotech, INC. | $36.41 | 2025 | Talvey, Carvykti, Darzalex |
| Celgene Corporation | $34.98 | 2023 | Pomalyst |
| Abbvie INC. | $31.75 | 2025 | |
| Astellas Pharma US INC | $29.93 | 2024 | Vyloy |
| Blueprint Medicines Corporation | $27.38 | 2025 | Ayvakit |
| Adaptive Biotechnologies Corporation | $26.27 | 2024 | Clonoseq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $24.06 | 2021 | |
| Tersera Therapeutics LLC | $23.63 | 2021 | |
| Array Biopharma INC | $20.68 | 2025 | Lorbrena |
| Daiichi Sankyo INC. | $19.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amaryllis Gil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.